Table 1.
Summary Statistics of Study Measures
| GSS (n=150) | Moore (n=350) | ||||
|---|---|---|---|---|---|
| Overall sample (n=500) n (%) | MRSA-neg (n=136) n (%) | MRSA-pos (n=14) n (%) | MRSA-neg (n=287) n (%) | MRSA-pos (n=63) n (%) | |
| Sex | |||||
| Male | 330 (66.0) | 113 (83.1) | 13 (92.9) | 173 (60.3) | 31 (49.2) |
| Female | 170 (34.0) | 23 (16.9) | 1 (7.1) | 114 (39.7) | 32 (50.8) |
| Race | |||||
| Black | 345 (69.0) | 36 (26.5) | 3 (21.4) | 254 (88.5) | 52 (82.5) |
| Other | 13 (2.6) | 7 (5.2) | 1 (7.1) | 4 (1.4) | 1 (1.6) |
| White | 142 (28.4) | 93 (68.4) | 10 (71.4) | 29 (10.1) | 10 (15.9) |
| Education | |||||
| No high school/no GED | 131 (26.2) | 0 (0) | 0 (0) | 103 (35.9) | 28 (44.4) |
| High school/GED | 143 (28.6) | 14 (10.3) | 2 (14.3) | 109 (38.0) | 18 (28.6) |
| Some college/ vocational | 111 (22.2) | 42 (30.9) | 5 (35.7) | 52 (18.1) | 12 (19.1) |
| College grad or more | 115 (23.0) | 80 (58.8) | 7 (50.0) | 23 (8.0) | 5 (7.9) |
| Yearly Income | |||||
| <25000 | 351 (70.5) | 24 (17.9) | 3 (21.4) | 264 (92.0) | 60 (95.2) |
| 25,001-50,000 | 62 (12.5) | 37 (27.6) | 6 (42.9) | 17 (5.9) | 2 (3.2) |
| 50,001-75,000 | 46 (9.2) | 36 (26.9) | 3 (21.4) | 6 (2.1) | 1 (1.6) |
| >75,000 | 39 (7.8) | 37 (27.6) | 2 (14.3) | 0 (0) | 0 (0) |
| Been arrested | |||||
| Yes | 40 (8.0) | 4 (2.9) | 0 (0) | 26 (9.1) | 10 (15.9) |
| No | 460 (92.0) | 132 (97.1) | 14 (100) | 261 (90.9) | 53 (84.1) |
| Hands on customer contact job | |||||
| Yes | 94 (18.8) | 49 (36.0) | 4 (28.6) | 39 (13.6) | 2 (3.2) |
| No | 406 (81.2) | 87 (64.0) | 10 (71.4) | 248 (86.4) | 61 (96.8) |
| Sexual orientation | |||||
| Different sex | 315 (63.0) | 95 (69.9) | 8 (57.1) | 69 (24.0) | 13 (20.6) |
| Same sex/both sexes | 185 (37.0) | 41 (30.1) | 6 (42.9) | 218 (76.0) | 50 (79.4) |
| Substance abuse (‘yes’ to street drugs)1 | |||||
| Yes | 253 (50.6) | 31 (22.8) | 4 (28.6) | 173 (60.3) | 45 (71.4) |
| No | 247 (49.4) | 105 (77.2) | 10 (71.4) | 114 (39.7) | 18 (28.6) |
| Sexually active1 | |||||
| Yes | 336 (67.2) | 111 (81.6) | 11 (78.6) | 177 (61.7) | 37 (58.7) |
| No | 164 (32.8) | 25 (18.4) | 3 (21.4) | 110 (38.3) | 26 (41.3) |
| # Sex Partners in last 30 days | |||||
| 0 | 220 (44.3) | 50 (36.8) | 4 (28.6) | 133 (46.3) | 33 (52.4) |
| 1 | 240 (48.3) | 70 (51.5) | 7 (50.0) | 135 (47.0) | 28 (44.4) |
| 2 or more | 37 (7.4) | 16 (11.8) | 3 (21.4) | 16 (5.7) | 2 (3.2) |
| STI2 | |||||
| Yes | 16 (3.2) | 8 (5.9) | 1 (7.1) | 6 (2.1) | 1 (1.6) |
| No | 484 (96.8) | 128 (94.1) | 13 (92.9) | 281 (97.9) | 62 (98.4) |
| Current abscess | |||||
| Yes | 39 (7.8) | 9 (6.6) | 2 (14.3) | 22 (7.7) | 6 (9.5) |
| No | 461 (92.2) | 127 (93.4) | 12 (85.7) | 265 (92.3) | 57 (90.5) |
| Prior Abscess1 | |||||
| Yes | 67 (13.4) | 16 (11.8) | 2 (14.3) | 38 (13.2) | 11 (17.5) |
| No | 433 (86.6) | 120 (88.2) | 12 (85.7) | 249 (86.8) | 52 (82.5) |
| Hospitalized1 | |||||
| Yes | 142 (28.5) | 25 (18.4) | 2 (14.3) | 85 (29.7) | 30 (47.6) |
| No | 357 (71.5) | 111 (81.6) | 12 (85.7) | 201 (70.3) | 33 (52.4) |
| On isolation3 | |||||
| Yes | 86 (17.3) | 17 (12.8) | 2 (14.3) | 55 (19.2) | 12 (19.0) |
| No | 410 (82.7) | 116 (87.2) | 12 (85.7) | 231 (80.8) | 51 (81.0) |
| HIV Medication | |||||
| Yes | 430 (86.7) | 125 (92.6) | 14 (100) | 242 (84.9) | 49 (79.0) |
| No | 66 (13.3) | 10 (7.4) | 0 (0) | 43 (15.1) | 13 (21.0) |
| On prophylaxis4 | |||||
| Yes | 86 (17.3) | 11 (8.1) | 0 (0) | 59 (20.8) | 16 (25.4) |
| No | 411 (82.7) | 125 (91.9) | 14 (100) | 225 (79.2) | 47 (74.6) |
| Viral Load | |||||
| Undetectable | 367 (73.4) | 115 (84.6) | 14 (100.0) | 196 (68.3) | 42 (66.7) |
| Detectable | 133 (26.6) | 21 (15.4) | 0 (0) | 91 (31.7) | 21 (33.3) |
| CD4 | |||||
| <200 | 58 (11.6) | 5 (3.7) | 0 (0) | 42 (14.6) | 11 (17.5) |
| 201-350 | 92 (18.4) | 20 (14.7) | 0 (0) | 55 (19.2) | 17 (27.0) |
| 351-500 | 113 (22.6) | 27 (19.9) | 6 (42.9) | 69 (24.0) | 11 (17.4) |
| >500 | 237 (47.4) | 84 (61.8) | 8 (57.1) | 121 (42.2) | 24 (38.1) |
Missing: Hospitalized n=1; Isolation n=4; Prophylaxis n=3; Income n=2; HIV Meds n=4; number of sex partners in 30 days n=3
1
Within previous 12 months.
2
Within previous 6 months.
3
On any type of isolation during any previous hospitalization.
4
Prophylaxis for HIV-associated opportunistic infections includes any use of: trimethoprim/sulfamethoxezole; dapsone; azithromycin; fluconazole.